Overview of questionnaires and scales of the quality of life and non-motor symptoms of patients with Parkinson’s disease
Authors:
R. Kozáková; R. Bužgová
Authors place of work:
Ostravská univerzita v Ostravě, Lékařská fakulta, Ústav ošetřovatelství a porodní asistence Vedoucí: prof. PhDr. Darja Jarošová, Ph. D.
Published in the journal:
Prakt. Lék. 2018; 98(2): 59-64
Category:
Of different specialties
Summary
For its rapid progression and specific symptoms of the disease, it is appropriate to provide multidisciplinary care for patients with Parkinson’s disease (PD), whose aim is to maintain the best quality of life for both the patient and their family. Abroad, questionnaires and scales are used to evaluate the patient’s health status, to determine disease progression and to provide subsequent individualized care. The aim of this review article is to describe and analyse the scales used in evaluating PD patients in the area of quality of life and non-motor symptoms. Having searched the electronic databases, 8 specific scales to assess the quality of life in PD patients and 2 scales for a complex assessment of non-motor symptoms in PD patients were found. All areas of care are best covered by the PDQ-39 (Parkinson’s Disease Questionnaire) designed to evaluate the quality of life. This scale is recommended for use in both clinical practice and research. For the evaluation of non-motor symptoms, the NMSQuest (Non-Motor Symptom Questionnaire) and NMSS (Non-Motor Symptom Scale) are most often used.
Keywords:
Parkinson disease – questionnaires – quality of life – scales – non-motor
Zdroje
1. Aarsland D, Perry R, Brown A, et al. Neuropathology of dementia in Parkinson’s disease: a prospective, community based study. Ann Neurol 2005; 58: 773–776.
2. Benito-Leon J, Cubo E, Coronell C. Impact of apathy on health-related quality of life in recently diagnosed Parkinson’s disease: the ANIMO study. Mov Disord 2012; 27(2): 211–218.
3. Bonnet AM, Jutras MF, Czernecki V, et al. Nonmotor symptoms in Parkinson‘s disease in 2012: relevant clinical aspects. Parkinsons Dis 2012; 198316.
4. Brown RG, Dittner A, Findley L, Wessely SC. The Parkinson fatigue scale. Parkinsonism Relat Disord 2005;11: 49–55.
5. Burn DJ, O’Brien JT. Use of functional imaging in parkinsonism and dementia. Mov Disord 2003; 18(Suppl 6): 88–95.
6. Calne S, Schulzer M, Mak E, et al. Validating a quality of life rating scale for idiopathic parkinsonism: Parkinson’s impact scale (PIMS). Parkinsonism Relat Disord 1996; 2(2): 55–61.
7. Cummings JL, Mega M, Gray K, Rosenberg-Thomson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308–2314.
8. De Boer AG, Wijker W, Speelman JD, De Haes JC. Quality of life in patients with Parkinson’s disease: Development of a questionnaire. J Neurol Neurosurg Psychiatry 1996; 61(1): 70–74.
9. Dubois B, Pillon B. Cognitive defi cits in Parkinson’s diseasse. J Neurol 1997; 244: 2–8.
10. Ellgring H, Seiler S, Perleth B, et al. Psychosocial aspects of Parkinson’s disease. Neurology 1993; 43: S41–44.
11. Elman LB, Houghton DJ, WU GF, et al. Palliative care in amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. J Palliat Med 2007; 10(2): 433–457.
12. Forsaa EB, Larsen JP, Wentzel-Larsen T, et al. A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol 2010; 67(8): 996–1001.
13. Fenelon G, Alves G. Epidemiology of psychosis in Parkinson’s disease. J Neurol Sci 2010; 289(1–2): 12–17.
14. Gallagher DA, Lees AJ, Schrag A. What are the most important nonmotor symptoms in patients with Parkinson‘s disease and are we missing them? Mov Disord 2010; 25(15): 2493–2500.
15. Goetz CG, Fahn S, Martinez-Martinin P, et al. Movement Disorder Society – sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): process, format and clinimetric testing plan. Mov Disord 2007; 22: 41–47.
16. Chaudhuri KR, Martinez-Martin P, Schapira AH, et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson’s disease: the NMSQuest study. Mov Disord 2006; 21: 916–923.
17. Chaudhuri KR, Pal S, DiMarco A, et al. The Parkinson’s disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2002; 73: 629–635.
18. Chaudhuri KR, Martinez-Martin P, Brown RG, et al. The metric properties of a novel non-motor symptoms scale for Parkinson’s disease: Results from an international pilot study. Mov Disord 2007; 22: 1901–1911.
19. Chaudhuri KR, Odin P, Antonini A, Martinez-Martin P. Parkinson’s disease: the non-motor issues. Parkinsonism Relat Disord 2011; 17(10): 717–723.
20. Chaudhuri, KR, Pal S., DiMarco A, et al. The Parkinson’s disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2002; 73(6): 629–635.
21. Chaudhuri RK, Rojo JM, Schapira AHV, et al. A proposal for a comprehensive grading of Parkinson‘s disease severity combining motor and non-motor assessments: meeting an unmet need. PLoS ONE 2013; 8(2): e57221.
22. Chaudhuri KR, Trenkwalder C, Rascol O, et al. King’s Parkinson’s disease pain scale, the first scale for pain in PD: An international validation. Mov Disord 2015; 30(12): 1623–1631.
23. The Irish Palliative Care in Parkinon’s Disease Group. Palliative care in people with Parkinson’s disease: Guidelines for proffesional healthcare workers on the assessment and management of palliative care needs in Parkinson’s disease and related Parkinsonian syndromes [on-line]. Dostupné z: https://www.ucc.ie/en/media/research/parkinsonscare/PalliativecareinPeoplewithParkinsonsdisease.pdf [cit. 2018-01-29].
24. Jenkinson C, Fitzpatrick R, Peto V, et al. The PDQ-8: Development and validation of a short-form Parkinson’s disease questionnaire. Psychol Health 1997; 12(6): 805–814.
25. Kleiner-Fisman G, Martine R, Lang AE, Stern MB. Development of a non-motor fluctuation assessment instrument for parkinson disease. Parkinsons Dis 2011; 2011: 292719.
26. Lee MA, Walker RW, Hildreth TJ, Prentice WM. A survey of pain in idiopathic Parkinson’s disease. J Pain Symptom Manage 2006; 32(5): 462–469.
27. Leentjens AFG, Dujardin K, Marsh L, et al. Symptomatology and markers of anxiety disorders in Parkinson’s disease: a cross-sectional study. Mov Disord 2011; 26(3): 484–492.
28. Leentjens AFG, Dujardin K, Pontone GM, et al. The Parkinson anxiety scale (PAS): Development and validation of a new anxiety scale. Mov Disord 2014; 29(8): 1035–1043.
29. Marinus J, Visser M, Verwey, NA, et al. Assessment of cognition in Parkinson’s disease. Neurology 2003; 61: 1222–1228.
30. Marinus J, Visser M, Martínez-Martín P, et al. A short psychosocial questionnaire for patients with Parkinson’s disease: the SCOPA-PS. J Clin Epidemiol 2003; 56(1): 61–67.
31. Martinez-Martin P, Jeukens-Visser M, Lyons KE, et al. Health related quality-of-life scales in Parkinson‘s disease: critique and recommendations. Mov Disord 2011; 26(13): 2371–2380.
32. Martinez-Martin P, Kurtis MM. Health-related quality of life as an outcome variable in Parkinson’s disease. Ther Adv Neurol Disord 2012; 5(2): 105–117.
33. Nègre-Pagès L, Regragui W, Bouhassira D, et al. Chronic pain in Parkinson’s disease: the cross-sectional French DoPaMiP survey. Mov Disord 2008; 23(10): 1361–1369.
34. Opara JA, Brola W, Leonardi M, Blaszczyk B. Quality of life in Parkinson’s disease. J Med Life 2012; 15(4): 375–381.
35. Pagonabarraga J, Kulisevsky J, Llebaria G, et al. Parkinson’s disease-cognitive rating scale: a new cognitive scale specific for Parkinson’s disease. Mov Disord 2008; 23(7): 998–1005.
36. Palma JA, Kaufmann H. Autonomic disorders predicting Parkinson’s disease. Parkinsonism Relat Disord 2014; 1: 94–98.
37. Peto V, Jenkinson C, Fitzpatrick R, Greenhall R. The development and validation of a short measure of functioning and well being for individuals with Parkinson’s disease. Qual Life Res 1995; 4(3): 241–248.
38. Ravina B, Camicioli R, Como PG, et al. The impact of depressive symptoms in early Parkinson disease. Neurology 2007; 69(4): 342–347.
39. Rektorová I. Kognitivní a behaviorální poruchy u demence při Parkinsonově nemoci a u demence s Lewyho tělísky. Neurol pro praxi 2004; 1: 15–21.
40. Rektorová I. Psychiatrické symtomy Parkinsonovy nemoci: diagnostika a léčba. Neurol pro praxi 2007; 8: 291–294.
41. Shearer J, Green C, Counsell CE, Zajicek JP. The impact of motor and non motor symptoms on health state values in newly diagnosed idiopathic Parkinson‘s disease. J Neurol 2012; 259(3): 462–468.
42. Schrag A, Jahanshahi M, Quinn N. How does Parkinson’s disease affect quality of life? A comparison with quality of life in the general population. Mov Disord 2000; 15: 1112–1118.
43. Sockeel PK, Dujardin D, Devos C, et al. The Lille apathy rating scale (LARS), a new instrument for detecting and quantifying apathy: validation in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2006; 77(5): 579–584.
44. Soh S-E, Morris ME, McGinley JL. Determinants of health-related quality of life in Parkinson’s disease: a systematic review. Parkinsonism Relat Disord 2011; 17(1): 1–9.
45. Švancara J, Sláma O, Kabelka L, a kol. Národní datová základna paliativní péče [online]. Praha: Ústav zdravotnických informací ČR, 2016. Dostupné z: http://www.paliativnidata.cz [cit. 2018-1-29].
46. Tom T, Cummings JL. Depression in Parkinson’s disease. Pharmacological characteristics and treatment. Drugs Aging 1998; 12(1): 55–74.
47. van den Berg M. Leben mit Parkinson: Entwicklung und psychometrische Testung des Fragenbogens PLQ. Neurol Rehabil 1998; 4: 221–226.
48. Welsh M, McDermott MP, Holloway RG, et al. Development and testing of the Parkinson’s disease quality of life scale. Mov Disord 2003; 18(6): 637–645.
49. Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 2010; 67(5): 589–595.
50. World Health Organization. Neurological disorders: public health challenges. Geneva: WHO 2006.
Štítky
Addictology Allergology and clinical immunology Anaesthesiology, Resuscitation and Inten Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric dermatology & STDs Paediatric gastroenterology Paediatric gynaecology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric clinical oncology Paediatric ENT Paediatric pneumology Paediatric psychiatry Paediatric radiology Paediatric urologist Diabetology Endocrinology Pharmacy Clinical pharmacology Physiotherapist, university degree Gastroenterology and hepatology Medical genetics Geriatrics Gynaecology and obstetrics Haematology Hygiene and epidemiology Hyperbaric medicine Vascular surgery Chest surgery Plastic surgery Medical virology Intensive Care Medicine Cardiac surgery Clinical speech therapy Clinical microbiology Nephrology Neonatology Neurosurgery Neurology Nuclear medicine Nutritive therapist Obesitology Ophthalmology Orthodontics Orthopaedics ENT (Otorhinolaryngology) Anatomical pathology Paediatrics Pneumology and ftiseology Burns medicine Occupational medicine General practitioner for children and adolescents General practitioner for adults Orthopaedic prosthetics Clinical psychology Radiodiagnostics Radiotherapy Rehabilitation Reproduction medicine Nurse Sexuology Forensic medical examiner Dental medicine Sports medicine Toxicology Trauma surgery Urology Laboratory Home nurse Phoniatrics Health Care Dental Hygienist Medical studentČlánok vyšiel v časopise
General Practitioner
2018 Číslo 2
- Advances in the Treatment of Myasthenia Gravis on the Horizon
- Memantine Eases Daily Life for Patients and Caregivers
Najčítanejšie v tomto čísle
- Overview of questionnaires and scales of the quality of life and non-motor symptoms of patients with Parkinson’s disease
- Survival after resection of oesophageal cancer
- Comparison of ankle brachial index with ultrasonographic examination of lower limb arteries in diabetics
- The parent-child physical activity of Czech families with normal weight children and overweight or obese children